RBC Capital analyst Trung Huynh initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- FDA grants traditional approval to encorafenib for CRC with BRAF V600E mutation
- Beam Therapeutics price target raised to $47 from $45 at BofA
- Helus Pharma appoints Freda Lewis-Hall to Board, Chair of Advisory Committee
- “J&J’s Claims of Superiority… Are False”: Johnson & Johnson Stock Rises despite Bayer Lawsuit
- Pfizer initiated with an Underweight at Barclays